HOME ▶ About Us ▶ Our Team


Message
We do our best to actualize our hopes and dreams for humankind: ‘perpetual youth’ and ‘a lifetime of health’. The results of such effort are continued with ‘Completion of KOREF’, ‘First completion for genome map as a Korean,’ ‘World’s first completed genome map for tiger, whale, horse, leopard,’ ‘Release of a high-speed, automatic liquid biopsy product,’ ‘CD-PRIME’ and ‘Certification of new medical technology and permit for Class 3 for AmoyDx ROS1 mutations detection kit from the Ministry of Food and Drug Safety’. We aim to become ‘a global company specializing in analyzing genomics based on genome ICT’ by working on mankind’s task of early diagnosis and prediction of cancer, selective prediction of rare diseases and treatment of genetic disorders with precision medicine.

We continue to challenge the development of new analytical technologies such as AI (Artificial Intelligence) algorithm and Multi-Omics. We have established a cooperative system with world-class scholars such as George McDonald Church and Prashant Gulab Ram Mali to secure global competitiveness in the genetic analysis market.
Through this cooperative system, the company will provide services in ‘Early diagnosis for cancer/diseases’, ‘Medical and health care’, ‘Customized precision medicine’, and ‘Gene therapy’.

Thank you from Clinomics Executives.

Our Team
Clinomics Inc. consists of highly experienced, core researchers to make innovation by fusing IT and
BT and holds global competitiveness by maintaining a cooperative relationship with international scholars
for advices on scientific technology.

CEO Kim ByungChul

Genetics Expert
  • Commercialized Asia’s first personalized genome analysis product
    (Theragen Etex HelloGene)
  • Developed and commercialized Korea’s first prenatal diagnosis research technology
    (Genome Care GenoMom)
  • Developed and commercialized Korea’s first CTC single cell mutant analysis technology
  • Received approval and sale for companion molecule analysis for anticancer drug
    (ROS1 fusion detection)

CEO / CSO Bhak Jong

Genome Expert
  • Commercialized Asia’s first personalized genome analysis product
    (Theragen Etex HelloGene)
  • Developed and commercialized Korea’s first prenatal diagnosis research technology
    (Genome Care GenoMom)
  • First Korean to construct standard genome and current developing Korean genome business
  • Attracted foreign investment from US genome business
    (900,000 USD from San Diego’s Diagnomics)
  • While working for Theragen Etex, attracted 20 Billion Won in Genome sector

COO Jeong Jongtae

Management Expert
  • CEO of Dream CIS
  • President of Hihr Consulting
  • Visiting Professor in Sogang University Business School
  • Adjunct Professor in Hanyang University
  • Adjunct Professor in Sungshin Women’s University
  • Researcher in Kookmin Bank Institute

Cho Yun Sung

Bioinformatics Expert / UNIST Ph.D.
  • Director for Clinomics Genome Business
  • Vice President at Geromics Corporation
  • Vice Manager at Genome Research Foundation
Global Advising Members

George McDonald Church

Professor at Harvard Medical School
  • Expert in Genetics and Synthetic Biology
  • Tech transfer/Advisory board in global high-tech biotech companies: Pacific Bioscience, Ion Torrent, 23andme, Gen9, Genomatica
  • Full CV @ http://arep.med.harvard.edu/gmc/

Prashant Gulab Ram Mali

CRISPR–Cas9 (Gene Scissors Technology) Expert
  • Assistant Professor of Bioengineering, University of California San Diego
  • Bioinformatics and Systems Biology, Moores Cancer Center
  • Institute for Genomic Medicine
  • Sanford Consortium For Regenerative Medicine, Cancer Cell Map Initiative

Cho Yoon-Kyoung

Microfluidics Technology Expert
  • Professor, Biomedical Engineering, UNIST
  • Group Leader, IBS center for Soft and Living Matter
  • Samsung CEO’s Award for Best Technology of the Year (2004, 2007)
  • “Lab Chip” (RSC), Editorial Board (‘13~ present)
  • “Analyst”(RSC), Advisory Board (‘12~present)
  • ETPC member, MicroTAS (‘13-’16)